Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Pancreatic Neoplasms 2Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Triple Negative Breast Neoplasms 1Thymoma 1Ovarian Neoplasms 1Mesothelioma 1Medical Oncology 1Lung Neoplasms 1Cholangiocarcinoma 1

Interventions

Cisplatin 11Pemetrexed 10pembrolizumab 9Nivolumab 3LMB-100 3budigalimab 2belinostat 2amatuximab 2Paclitaxel 2Docetaxel 2Dexamethasone 2Cyclophosphamide 2Carboplatin 2Calcium Dobesilate 2venetoclax 1trametinib 1tislelizumab 1tazemetostat 1talazoparib 1spartalizumab 1sodium thiosulfate 1sargramostim 1ruxolitinib 1rovalpituzumab tesirine 1olaparib 1obinutuzumab 1naptumomab estafenatox 1irinotecan sucrosofate 1fludarabine 1enzalutamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Mesothelioma × anetumab ravtansine × Clear all
NCT02639091 2019-11-07

Phase Ib Study of Anetumab Ravtansine in Combination With Pemetrexed and Cisplatin in Mesothelin-expressing Solid Tumors

Bayer

Phase 1 Completed
36 enrolled
Other solid neoplasmThoracic

Lung Neoplasms, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡